Oruka Therapeutics Inc
ORKAHealthcare|Biotechnology|USA
$86.79
-1.48 (-1.68%)
Tangible Book
$9.64
About
Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.
Stock Price
+516.8%(1Y)
Pipeline Summary
6 total trials2
Phase 1
4
Phase 2
0
Phase 3
0
Phase 4
Recruiting: 3Active: 2Completed: 1
Active Trials (5)
Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis
NCT07474792Plaque Psoriasis
Phase 2Recruiting
Enrollment: 160 participants
ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque Psoriasis
NCT07090330Plaque Psoriasis
Phase 2Active
Enrollment: 80 participants
ORKA-002-211 A Phase I Study to Evaluate ORKA-002 in Healthy Volunteers Following A Single Dose
NCT06944379Healthy Volunteers
Phase 1Active
Enrollment: 24 participants
Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis
NCT07290569Plaque Psoriasis
Phase 2Recruiting
Enrollment: 160 participants
An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis
NCT07449702Plaque Psoriasis
Phase 2Recruiting
Enrollment: 240 participants
BioScore
4.3/10
Cautious
Ownership
Recent Insider Trades
Fairmount Healthcare Fund II L.P.SELL
2026-07-013,553,410 shares @ $84.43
Sandler Laura LeeSELL
2026-07-015,000 shares @ $94.42
Agarwal ArjunSELL
2026-06-221,587 shares @ $80.95
Sandler Laura LeeSELL
2026-06-15600 shares @ $69.69
Quinlan Paul TSELL
2026-06-15733 shares @ $69.69
Recent News
2026-07-13 11:02:58
2026-07-02 14:28:25
2026-07-02 02:03:16
2026-07-01 16:38:29
2026-06-23 11:02:59
Data last updated: Jul 13, 2026, 12:40 PM